Feb. 21 at 4:45 PM
$MSOS $TLRY $CGC $ACB
AI Overview
Here is an analysis of why rescheduling may not help Tilray:
1. Lack of Direct U.S. Cannabis Operations
No Immediate Revenue Impact: Tilray is a Canadian-based producer. Rescheduling does not equate to full legalization; it does not allow foreign companies to export or sell cannabis into the U.S. market.
Limited Exposure: Unlike US-based Multi-State Operators (MSOs), Tilray lacks direct, state-licensed, touch-the-plant operations in the U.S. that would directly benefit from tax relief.
2. Failure to Solve Structural Financial Issues
Ongoing Cash Burn and Losses: Even if the overall market sentiment improves, Tilray has faced significant, ongoing net losses and cash burn. Rescheduling doesn't fix underlying operational inefficiencies.
High Dilution Risk: The company has a history of using At-The-Market (ATM) issuances, leading to shareholder dilution.
Weak Margins: Gross margins have been pressured by a mix of cannabis and beverage sales.
Continued…
